MedPath

A clinical trial to study the effect of 3 drugs, dexmedetomidine, fentanyl, ketamine in addition to lignocaine nebulization for anesthetizing airway in patients undergoing awake fibreoptic intubation.

Completed
Conditions
Medical and Surgical,
Registration Number
CTRI/2023/01/049238
Lead Sponsor
Yenepoya medical college hospital
Brief Summary

This study is a randomized, double blind, parallel group, single centre trial comparing the effect of dexmedetomidine(1 mcg/kg), fentanyl( 2 mcg/kg), ketamine( 2mg/kg) in addition to 4 % lignocaine (160mg) nebulization during awake fibreoptic intubation. The primary outcome measures will be the cough score and rate of glottic closure at the time from the starting of intubation till the tube reaches the trachea. The secondary outcomes will be sedation score and to observe for other adverse effects.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
84
Inclusion Criteria

Patients under the category of ASA I/II(American Society of Anaesthesiologist).

Exclusion Criteria

1.Previous Airway surgery 2.Anticipated difficult airway 3.Nasal Trauma 4.Allergy to Local Anesthetics.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.To determine the cough score.the time from the starting of intubation till the tube reaches the trachea (about 30sec)
2.To determine the rate of glottic closure during bronchoscopy and intubation.the time from the starting of intubation till the tube reaches the trachea (about 30sec)
Secondary Outcome Measures
NameTimeMethod
1.To evaluate sedation score.2.To observe for any other adverse effects.

Trial Locations

Locations (1)

Yenepoya Medical College Hospital

🇮🇳

Kannada, KARNATAKA, India

Yenepoya Medical College Hospital
🇮🇳Kannada, KARNATAKA, India
Dr Smita Musti
Principal investigator
9886125842
smitamusti@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.